Efficacy and Safety of Canagliflozin in the Treatment of Type 2 Diabetes With Mild Cognitive Impairment
NCT07711171
Summary
The prevalence of cognitive dysfunction in diabetic patients is high, which seriously affects the quality of life of patients, and early intervention is of great significance. Central nervous system insulin resistance plays a key role in the pathogenesis of cognitive dysfunction in diabetic patients. Central insulin resistance observed by functional magnetic resonance imaging (fMRI), may serve as an alternative endpoint for assessing cognitive function. Sodium glucose cotransporter 2 inhibitor (SGLT2i) may improve cognitive impairment by improving central insulin resistance.
Eligibility
Inclusion Criteria: * age: 40-75 years old; * HbA1c: 7.0 - 10.0%; * Moca scale total score between 20-26 (duration of education is more than 10 years) or total score between 20 and 25 (duration of education is less than 10 years); * sign informed consent; Exclusion Criteria: * left-handedness; * duration of diabetes is less than 6 years; * inability to complete central nervous system magnetic resonance imaging; * alcohol or drug addiction history; * use of other oral hypoglycemic drugs within 90 days prior to enrollment except for metformin; * Family or past history of neurological or psychiatric disorders, pancreatitis, medullary thyroid cancer and multiple endocrine adenomatosis; * History of recurrent urinary tract infection and malignant tumor; * History of severe gastrointestinal diseases and gastroenteric surgery; * Pregnancy/lactation status; * Abnormal liver function (liver enzyme index is more than 2.5 times the upper limit of the reference range) or abnormal kidney function (estimated glomerular filtration rate is less than 45ml/min); Type 1 diabetes; other diseases or conditions that reduce the possibility of enrollment or complicate enrollment, such as frequent changes in the working environment and unstable living environment, which are likely to cause loss of follow-up, according to the judgment of the researchers;
Conditions3
Interventions3
Related trials
- Sitagliptin or BeiDouGen Capsule Improve the Pregnancy Outcome in Patients with PCOS — Peking University Third Hospital
- Sun Yat-Sen Treatment Strategy for Enhancing Response in Muscle-invasive Bladder Cancer — Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- Sitagliptin in Recurrent/Progressive Grade 4 Glioma — Kailin Yang, MD, PhD
- A Phase 2 and Pharmacodynamic Study of Sitagliptin in Patients With Progressive Grade 4 Gliomas — Case Comprehensive Cancer Center
- Comparative Effectiveness of Two Initial Combination Therapies in Patients With Recent Onset Diabetes — The University of Texas Health Science Center at San Antonio
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
NCT07711171